ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis

Giacomo Lazzarino 1,†, Renata Mangione 2,3,4, Antonio Belli 4, Valentina Di Pietro 4, Zsuzsanna Nagy 4, Nicholas M. Barnes 4, Lars Bruce 5, Bernardo M. Ropero 6, Lennart I. Persson 6, Benedetta Manca 7, Miriam Wissam Saab 8, Angela M. Amorini 8,9, Barbara Tavazzi 1,2,3,†, Giuseppe Lazzarino 8,9,† and Ann Logan 9,10,*

Abstract: Oxidative/nitrosative stress and mitochondrial dysfunction is a hallmark of amyotrophic lateral sclerosis (ALS), an invariably fatal progressive neurodegenerative disease. Here, as an exploratory arm of a phase II clinical trial (EudraCT Number 2017-005065-47), we used high performance liquid chromatography (HPLC) to investigate changes in the metabolic profiles of serum from ALS patients treated weekly for 4 weeks with a repeated sub-cutaneous dose of 1 mg/kg of a proprietary low molecular weight dextran sulphate, called ILB®. A significant normalization of the serum levels of several key metabolites was observed over the treatment period, including N-acetylaspartate (NAA), oxypurines, biomarkers of oxidative/nitrosative stress and antioxidants. An improved serum metabolic profile was accompanied by significant amelioration of the patients’ clinical conditions, indicating a response to ILB® treatment that appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes.

Keywords: amyotrophic lateral sclerosis; low molecular weight-dextran sulphate; serum biomarkers; energy metabolism; mitochondrial dysfunction; N-acetylaspartate; amino acids; oxidative/nitrosative stress; antioxidants; HPLC

1. Introduction

Amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) is the most common type of motor neuron disease. It is invariably a fatal disease, affecting most populations of motor neurons. The most important degeneration of neuronal cells occurs
in motor neurons in the spinal cord, brain stem and brain. The disease begins focally in the central nervous system and then spreads relentlessly [1]. The clinical diagnosis, defined by progressive signs and symptoms of upper and lower motor neuron dysfunction, is confirmed by clinical findings, electromyography, blood and cerebrospinal fluid (CSF) analysis. Although the disease is heterogeneous, most patients die of respiratory muscle weakness less than 3–5 years from symptom-onset. Like other age-related neurodegenerative diseases, ALS has genetic, metabolic and environmental triggers.

As yet, there is no cure for ALS, and management is focused on a combination of neuroprotective medication, multidisciplinary clinics and respiratory support. To date, there is one medication (riluzole (Rilutek®), approved originally in the USA in 1995) with anti-glutamatergic properties that prolongs survival, although the effect is limited typically to a few months of additional survival in ALS [2]. Numerous trials have so far been unable to identify any agent that reverses or even halts symptoms. Researchers now aim to slow disease progression by targeting known pathophysiological pathways or genetic defects.

The deranged neuronal function that is associated with the oxidative/nitrosative stress and mitochondrial dysfunction that characterizes the pathophysiological progress of neurodegenerative conditions such as ALS [3] is reflected by changes in related metabolites in blood. When measured, these metabolites can be used as biomarkers of tissue function and, therefore, of disease progression and/or patient response to treatment [4].

The proprietary low molecular weight dextran sulphate (LMW-DS) under investigation in this study is a novel patented formulation of a modified glycosaminoglycan called ILB® (Tikomed AB, Viken, Sweden), which exerts neurotrophic effects through the release and modulation of growth factors including HGF [5] and has been shown to restore brain energy metabolism in the injured brain after severe traumatic brain injury in rats [6].

Here, we report that repeated ILB® administration over four weeks leads to a significant attenuation of the levels of key serum metabolites related to neural damage, oxidative/nitrosative stress and mitochondrial derangement in a cohort of patients with ALS who had participated in the clinical trial entitled ‘A single-center, open single-arm study on the safety, tolerability and efficacy of subcutaneously administered ILB® in patients with amyotrophic lateral sclerosis’; trial registration: EudraCT Number 2017-005065-47. The primary outcomes of this clinical trial are reported elsewhere [7].

2. Materials and Methods
2.1. Trial Oversight

The clinical trial was a phase IIa, single-center, open label, single-arm proof of concept study of 13 heterogeneous patients with ALS of intermediate disease severity, with safety and tolerability of subcutaneously (s.c.) administered ILB® as the primary endpoints. The study (EudraCT number 2017-005065-47) was conducted at the Sahlgrenska University Hospital, Gothenburg, Sweden. The trial was overseen and approved by the Ethics Committee of the University of Gothenburg and by the Swedish Medical Products Agency (reference number 21,788). The trial was sponsored by Tikomed AB, who had no influence on the conduct of the trial and was not involved in data collection or analysis. The study protocol is described in Supplementary Table S1, and the verbal and written information provided to the patients were in accordance with the Declaration of Helsinki. The underpinning data that support the findings in this study are available from the EU Clinical Trials Register [8].

2.2. Patients and Controls

Thirteen patients of either sex with a definite diagnosis of sporadic or genetic forms of ALS and either slow or rapid progression were recruited into the ILB® clinical trial at the Sahlgrenska University Hospital. The male:female ratio was 10:3, mean age ± SD was 56.5 ± 13.3 years and mean ALSFRS-R score ± SD at screening was 36.3 ± 6.7. Individuals were included in the drug trial after giving informed written consent after the diagnosis of ALS was confirmed as definite according to the El Escorial criteria, if there was no other major degenerative or inflammatory disease and if there was a ventilatory capacity of no
less than 65% of normal predicted Forced Vital Capacity (FVC) at screening. Patients had to be free of riluzole or lamotrigine for a minimum of 28 days for inclusion in the trial. Full details of the inclusion/exclusion criteria are described in Supplementary Table S1 and elsewhere [8].

A group of 163 age and sex matched healthy subjects (58 ± 14 years, 111 males and 52 females), recruited during the last three years at the Catholic University of Rome among the personnel who underwent the annual health check-up, were used as controls. Written informed consent was obtained from each participant according to the Declaration of Helsinki.

2.3. Clinical Assessment of Patients with ALS Using the ALSFRS-R

Disease progression during the clinical trial was assessed at each visit using ALSFRS-R scores, a physician-generated validated assessment of the patient’s degree of functional impairment, which was evaluated serially to assess objectively any impact of treatment on the progression of disease [9]. The ALSFRS-R included questions and observations that allowed the patient’s level of functional impairment in performing 12 aspects of physical function, including speech, salivation, swallowing, handwriting, cutting food, climbing stairs, turning in bed, walking, dressing and hygiene, difficulty in breathing, shortness of breath while lying down and breathing insufficiency. Tasks were rated on a five-point scale from 0 = cannot do, to 4 = normal ability. Individual item scores were summed to produce a reported score of between 0 = worst and 48 = best.

2.4. Investigational Medicinal Product (IMP), Dosing and Administration

The active pharmaceutical ingredient of the IMP was an LMW-DS having a mean molecular weight of 5 kDa containing molecules spanning approximately 3–8 kDa with on average 20% sulphation. ILB® is a unique and distinct LMW-DS formulation whose structure, formulation, synthesis and structure has been previously described in a published patent document (publication number: WO 2016/076780—New dextran sulphate). ILB® was provided by Tikomed AB in 10 mL vials containing a solution of 20 mg/mL ILB® in 9 mg/mL NaCl. A single batch of drug was used throughout the study (batch #8059701). ILB® was injected s.c. on alternating sides of the abdomen by the clinical personnel at the Sahlgrenska University Hospital. Five injections of 1 mg/kg, with a weekly dosing interval, were administered in total over 29 days. The exact dose administered depended on the patient’s body weight immediately prior to the first ILB® administration.

2.5. Serum Sampling

Blood samples were taken for metabolic biomarker analysis immediately prior to the first ILB® injection at day 0 (pre-treatment: Pre) and again at day 36 (one week post-treatment: Post). Peripheral venous blood samples were collected from both patients and controls after at least 15 min of complete rest, using the standard tourniquet procedure, from the antecubital vein into a single VACUETTE® polypropylene tube containing serum separator and clot activator (Greiner-Bio One GmbH, Kremsmunster, Austria). After 30 min at room temperature, blood withdrawals were centrifuged at 1890 × g for 10 min and the resulting serum samples saved at temperatures not higher than −20 °C until analysis.

2.6. List of ALS Patient Samples, Sample Processing and Analyses

The laboratory received, processed and analyzed serum samples from the patients with ALS (coded as reported in Table 1) in blind. A progressive number, from 1 to 26 was given to each sample. After all analyses were completed, each serum sample was designated either as Day 0 (pre-treatment) or Day 36 (post-treatment), with the final ILB® treatment administered on Day 29.
Table 1. Coding of the serum samples.

| Sample Number | Subject Number and Sampling Time |
|---------------|----------------------------------|
| 1             | Subject 101, Day 0               |
| 2             | Subject 101, Day 36              |
| 3             | Subject 102, Day 0               |
| 4             | Subject 10, Day 36               |
| 5             | Subject 103, Day 0               |
| 6             | Subject 103, Day 36              |
| 7             | Subject 104, Day 0               |
| 8             | Subject 104, Day 36              |
| 9             | Subject 105, Day 0               |
| 10            | Subject 105, Day 36              |
| 11            | Subject 106, Day 0               |
| 12            | Subject 106, Day 36              |
| 13            | Subject 107, Day 0               |
| 14            | Subject 107, Day 36              |
| 15            | Subject 108, Day 0               |
| 16            | Subject 108, Day 36              |
| 17            | Subject 109, Day 0               |
| 18            | Subject 109, Day 36              |
| 19            | Subject 110, Day 0               |
| 20            | Subject 110, Day 36              |
| 21            | Subject 111, Day 0               |
| 22            | Subject 111, Day 36              |
| 23            | Subject 112, Day 0               |
| 24            | Subject 112, Day 36              |
| 25            | Subject 113, Day 0               |
| 26            | Subject 113, Day 36              |

An aliquot of each serum sample (500 µL) from either controls or patients with ALS was supplemented with 1.0 mL of HPLC-grade acetonitrile, vortexed for 60 s, centrifuged at 20,690 × g for 15 min at 4 °C to precipitate proteins [10,11]. Supernatants were washed with large volumes of HPLC-grade chloroform to remove acetonitrile, centrifuged and the upper aqueous phases were transferred to different tubes, clearly labeled to identify the sample and stored at −80 °C until analyzed to determine different water-soluble compounds.

A second aliquot of 300 µL of each serum sample was protected from light and then processed to extract fat-soluble vitamins and antioxidants, using a method described in detail elsewhere [12]. Briefly, samples were supplemented with 1 mL of HPLC-grade acetonitrile, vortexed vigorously for 60 s and incubated at 37 °C for 1 h in a water bath under agitation, to maximize extraction of lipid soluble compounds. Samples were then centrifuged at 20,690 × g for 15 min at 4 °C to remove precipitated proteins and the clarified supernatants stored at −80 °C until the HPLC analysis of fat-soluble vitamins and antioxidants.

In the aqueous phase of deproteinized serum samples, creatinine, uracil, β-pseudouridine, cytidine, hypoxanthine, xanthine, uric acid, uridine, inosine, guanosine, orotic acid, malondialdehyde (MDA), nitrite, nitrate, N-acetylaspartate (NAA) were separated and quantified by direct HPLC methods, with no sample derivatization [10,11,13]. Additionally, aspartate (ASP), glutamate (GLU), asparagine (ASN), serine (SER), glutamine (GLN), histidine (HIS), glycine (GLY), threonine (THR), citrulline (CITR), arginine (ARG), alanine (ALA), taurine (TAU), γ-aminobutyrate (GABA), tyrosine (TYR), S-adenosylhomocysteine (SAH), L-cystathionine (L-CYSTAT), valine (VAL), methionine (MET), tryptophan (TRP), phenylalanine (PHE), isoleucine (ILE), leucine (LEU), ornithine (ORN), lysine (LYS) were separated and quantified by HPLC using pre-column derivatization with orthophtaldehyde (OPA) [14].

The following fat-soluble vitamins and antioxidants in deproteinized serum samples were separated and quantified by HPLC according to a method set up in our laboratory [12]:...
all trans-retinoic acid, all trans-retinol (vitamin A), α-tocopherol (vitamin E), γ-tocopherol, coenzyme Q10, astaxanthin, phytoene, lutein, zeaxanthin, trans-β-apo-8’-carotenal, β-cryptoxanthin, lycopene, α-carotene, β-carotene, violaxanthin, 25-hydroxycholecalciferol (vitamin D3).

All HPLC analyses were carried out using a Surveyor HPLC apparatus (Thermo Fisher Scientific, Rodano, Milan, Italy) equipped with a highly sensitive 5 cm light-path flow cell diode array UV detector, setup for acquisition between 200 and 550 nm wavelengths. Water-soluble compounds, free amino acids and amino group containing compounds were loaded (100 and 25 µL, respectively) onto a Hypersil C-18, 250 × 4.6 mm, 5 µm particle size column (Thermo Fisher Scientific, Rodano, Milan, Italy), while fat-soluble compounds (200 µL) were loaded onto a Hypersil Gold C-18, 200 × 4.6 mm, 5 µm particle size column (Thermo Fisher Scientific, Rodano, Milan, Italy). Both columns used were provided with their own guard columns. Data acquisition and analysis were performed using the ChromQuest® software package provided by the HPLC manufacturer. Quantification of uracil, β-pseudouridine, cytidine, hypoxanthine, xanthine, uric acid, uridine, inosine, guanosine, orotic acid, malondialdehyde (MDA) was carried out at 260 nm wavelength [10,11,13]. Creatinine was quantified at 234 nm, whilst NAA, nitrite and nitrate were quantified at 206 nm wavelength [10,11,13]. OPA-amino acids and amino group-containing compound derivatives were quantified at 338 nm [14]. Lastly, fat-soluble vitamins and antioxidants were quantified at wavelengths between 260 and 500 nm [12].

To verify reproducibility of chromatographic runs, a mixture containing proper ultra-pure standards with known concentrations was analyzed every other five serum samples.

Additionally, in all protein-free serum samples the concentration of lactate was determined spectrophotometrically using the method described by Artiss et al. [15].

2.7. Statistics

Comparison of the pre- and post-treatment subgroups was performed by the two-tailed Student’s t-test for paired samples. The comparison of each subgroup with the group of control healthy subjects was carried out by the one-way analysis of variance (ANOVA), followed by the Dunnett’s post-hoc test. Differences with \( p < 0.05 \) were considered statistically significant.

3. Results

3.1. Raw Data

Supplementary Tables S2–S4 report the raw data, means, standard deviations and \( p \)-values (significant results of the Student’s \( t \)-test are marked in red) of the circulating concentrations of metabolites found in patients with ALS. Only those compounds resulting in statistically significant differences on the pre-post ILB® administration comparison (hypoxanthine, xanthine, uric acid, MDA, nitrite, nitrate, N-acetylaspartate, nitrite + nitrate and sum of oxypurines, Table S2; citrulline, alanine and ornithine/citrulline ratio, Table S3; α-tocopherol and γ-tocopherol, Table S4) are indicated. Similarly, Table S5 reports the serum levels of the aforementioned compounds recorded in the group of 163 age and sex matched healthy controls.

3.2. ILB® Improves Patients’ Clinical Conditions and Decreases Neuronal Damage and Energy Metabolism Impairment

Data summarized in Table 2 show the effects of ILB® treatment on the clinical parameters used for assessing symptom progression of ALS. At the end of the ILB® administration period, a +8.6% increase in ALSFRS-R was observed (\( p < 0.001 \) compared to pre-treatment). Interestingly, at the time of blood withdrawal for the biochemical analyses of selected circulating metabolites (i.e., one week after the end of ILB® treatment), clinical symptoms of patients with ALS displayed a further improvement leading to a final +13.3% overall increase in ALSFRS-R (\( p < 0.002 \) compared to pre-treatment).
Table 2. Change in ALS patient functional rating over the ILB® treatment period assessed by ALSFRS-R.

| Day                  | ALSFRS-R ± SD |
|----------------------|---------------|
| 0 (Pre-treatment)    | 36.1 ± 6.7    |
| 29 (Final treatment)| 39.2 ± 6.3 *  |
| 36 (Post-treatment) | 40.9 ± 6.9 **|

* Significantly different compared to day 0, p < 0.001. ** Significantly different compared to day 0, p < 0.002.

Figure 1 illustrates the changes in the circulating concentrations of NAA (a), uric acid (b) and sum of oxypurines (hypoxanthine + xanthine + uric acid) (c) recorded in patients with ALS before and after ILB® administration. ILB® treatment produced a significant reduction in ALS-related neuronal damage, as clearly evidenced by the 41.7% decrease (p < 0.05 compared to pre-treatment) of the serum levels of the neuron specific compound NAA. At the same time, ILB®-treated patients had decreased serum concentrations of uric acid (the final product of adenine nucleotide degradation) and the sum of oxypurines, suggesting an ILB®-induced amelioration of cell energy metabolism. It is worth underlining that, when compared with the group of healthy controls, patients with ALS, either before or after treatment, had significantly different values in any of the aforementioned compounds (p < 0.001).

![Figure 1](image-url)
before (Pre) and after (Post) ILB® treatment were, respectively, 270.50 ± 57.90, 397.10 ± 70.32 and 371.40 ± 71.98 µmol/L serum. Means ± S.D. of sum of oxypurines in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 276.80 ± 58.45, 407.60 ± 69.34 and 381.20 ± 72.38 µmol/L serum. * Significantly different from Controls, \( p < 0.001 \). ** Significantly different from Pre, \( p < 0.05 \).

3.3. ILB® Decreases ALS-Related Oxidative/Nitrosative Stress

As shown in Figure 2, patients with ALS after ILB® treatment had significantly lower circulating biomarkers of both reactive oxygen species-mediated lipid peroxidation (a) (−33% in MDA values, \( p < 0.05 \)) and of nitric oxide overproduction (b) (−10.2% in circulating nitrite + nitrate, \( p < 0.05 \)), suggesting beneficial effects of the drug upon the mechanisms underlying insurgence of oxidative/nitrosative stress. Notwithstanding the treatment effects, when compared with the group of healthy controls, patients with ALS, either before or after treatment, had significantly different values in both the aforementioned compounds (\( p < 0.001 \)).

![Figure 2](image_url)

**Figure 2.** Box plots reporting minimum, maximum, median, 25% and 75% percentiles of the serum concentrations of lipid peroxidation end product (MDA, (a)) and stable compounds of nitric oxide metabolism (nitrite + nitrate, (b)) in 13 patients with ALS before (Pre) and after (Post) ILB® treatment. The values measured in a group of 163 healthy controls are also reported. (○) Open circles are the values of metabolites in each subject enrolled in the study. Means ± S.D. of MDA in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 0.066 ± 0.048, 0.190 ± 0.114 and 0.128 ± 0.046 µmol/L serum. Means ± S.D. of nitrite + nitrate in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 30.90 ± 9.67, 53.98 ± 12.55 and 48.47 ± 12.25 µmol/L serum. * Significantly different from Controls, \( p < 0.001 \). ** Significantly different from Pre, \( p < 0.05 \).
3.4. ILB® Ameliorates ALS-Induced Changes of Serum Amino Acids

Of the 25 amino acids and amino group-containing compounds that were quantified in serum samples of patients with ALS before and after ILB® administrations, significant differences were found in the case of alanine (α) (−12.7%, \( p < 0.05 \)), citrulline (β) (−21.2%, \( p < 0.05 \)) and the ornithine/citrulline ratio (c) (+44%, \( p < 0.05 \)), indicating an effect on muscular protein turnover and consistent with the significant decrease of nitric oxide production and counteraction of nitrosative stress (Figure 3). It is important to note that, in the case of alanine and citrulline, the administration of ILB® was able to restore serum values equal to those found in healthy control subjects.

![Figure 3. Box plots reporting minimum, maximum, median, 25% and 75% percentiles of the serum concentrations of amino acids related to muscular protein degradation (ALA, (a)) and to nitric oxide generation (CITR, (b) and ORN/CITR ratio, (c)) in patients with ALS before (Pre) and after (Post) ILB® treatment. The values measured in a group of 163 healthy controls are also reported. (○) Open circles are the values of metabolites in each subject enrolled in the study. Means ± S.D. of ALA in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 364.40 ± 95.50, 429.00 ± 85.96 and 374.70 ± 83.43 µmol/L serum. Means ± S.D. of CITR in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 18.82 ± 4.22, 23.59 ± 7.03 and 18.60 ± 5.10 µmol/L serum. Means ± S.D. of ORN/CITR in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 4.47 ± 1.78, 1.52 ± 0.68 and 2−19 ± 1.03. * Significantly different from Controls, \( p < 0.001 \). ** Significantly different from Pre, \( p < 0.05 \).]

3.5. ILB® Improves the Pattern of Circulating Fat-Soluble Antioxidants

As shown in Figure 4, the group of 13 patients with ALS, one week after of drug administration, had significantly higher serum values of the most important fat-soluble antioxidant. In particular, serum levels of the two most abundant congeners of vitamin E found in the European diet, i.e., \( \alpha \)-tocopherol (a) and \( \gamma \)-tocopherol (b), increased by 21.5% and 39.2% (\( p < 0.05 \)), respectively, thus conferring a better protection to the unsaturated...
fatty acids of membrane phospho-lipids that are the main target of reactive oxygen species-mediated lipid peroxidation. However, both compounds were significantly lower than the values measured in healthy controls, either before or after drug administration ($p < 0.001$).

Figure 4. Box plots reporting minimum, maximum, median, 25% and 75% percentiles of the serum concentrations of the main vitamin E congeners ($\alpha$-tocopherol, (a) and $\gamma$-tocopherol, (b)) in patients with ALS before (Pre) and after (Post) ILB® treatment. The values measured in a group of 163 healthy controls are also reported. (○) Open circles are the values of metabolites in each subject enrolled in the study. Means ± S.D. of $\alpha$-tocopherol in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 25.03 ± 5.78, 9.35 ± 5.54 and 11.70 ± 8.50 µmol/L serum. Means ± S.D. of $\gamma$-tocopherol in controls, patients with ALS before (Pre) and after (Post) ILB® treatment were, respectively, 1.05 ± 0.28, 0.497 ± 0.139 and 0.692 ± 0.367 µmol/L serum. * Significantly different from Controls, $p < 0.001$. ** Significantly different from Pre, $p < 0.05$.

4. Discussion

The relevance of metabolic dysfunction to acute and chronic neurodegeneration has clearly been established in the last decade [16,17]. ALS has also been included in the list of chronic, progressive neurodegenerative disorders in which metabolic alterations, particularly those occurring to the so-called “central metabolism” [18,19], have been indicated not only as biochemical signatures of the disease [20] but also as molecular mechanisms connected to its pathogenesis and progression [21,22]. Hence, drug treatments capable of improving ALS-induced metabolic dysfunctions are considered as potentially promising therapies to be investigated in this still “orphan drug disease” [23,24]. Results reported in the present clinical trial strongly suggest that ILB® administration produces metabolic benefits that are translated into evident improvements in clinical outcome for patients with ALS.
When evaluating the results of the targeted metabolic analyses, in serum from 13 patients with ALS (before and one week after 29 days of ILB® administration), of the 55 quantified compounds that are connected to energy metabolism, mitochondrial function, oxidative/nitrosative stress, water- and fat-soluble antioxidant defenses, one of the most remarkable differences occurred with the levels of NAA. In accordance with the data of Simone et al. [25], we found that patients with ALS had nearly five-times higher values of circulating NAA than those of control healthy subjects. Although NAA serum levels after ILB® treatment were still 2.4 times higher than the values recorded in controls, a 41.7% decrease compared to pre-treatment levels was detected. Previous clinical studies have demonstrated that brain levels of NAA in patients with ALS are significantly lower than those of healthy subjects [26–28] and correlates negatively with time of patients’ survival [29]. Furthermore, in a mouse model of selective motoneuronal loss, mimicking the primary pathology associated with ALS, we have very recently found a dramatic depletion of NAA in spinal cord extracts [30]. It has been shown that changes in cerebral NAA levels under pathological conditions are not simply due to neuronal loss but may also occur under conditions of mitochondrial dysfunction with consequent energy penalty [31–35]. Therefore, it is tempting to speculate that lower serum NAA concentrations in the cohort of patients with ALS following ILB® administration was due to improved cerebral mitochondrial metabolism. This is supported by recent evidence showing that ILB® administration dose-dependently restores brain energy metabolism and NAA concentrations following severe traumatic brain injury in an animal model in vivo [6].

In accordance with this hypothesis, we found that patients with ALS after ILB® treatment had decreased serum levels of both uric acid and sum of oxypurines (hypoxanthine + xanthine + uric acid). These compounds, particularly uric acid, represent the end products of the adenine nucleotide degradation pathway occurring at a high rate under conditions of impaired energy metabolism, i.e., when imbalance between ATP production and consumption takes place [36,37]. Increased oxypurines have been observed during coronary bypass surgery [38], following traumatic brain injury [39], in patients affected by multiple sclerosis (correlating with disease progression, clinical subtype and neuroradiological findings) [40,41], as well as under various experimental conditions of cellular energy penalty [42–44] including those found in muscle tissue in an ALS-like murine model of motoneuron ablation [30]. Recently, using 31P-magnetic resonance spectroscopy for the quantification of energy-related metabolites in vivo, it has been found that patients with ALS have evident mitochondrial dysfunction in both brain and muscle tissues [45]. Therefore, the increase in serum uric acid and sum of oxypurines evident in the patients with ALS, compared to levels in healthy controls, may represent a biochemical signature of impaired neuronal and muscle metabolism that can be attenuated successfully by the treatment with ILB®.

Numerous pathological conditions characterized by protracted mitochondrial dysfunction are accompanied by increased production of reactive oxygen (ROS) and reactive nitrogen species (RNS) triggering the insurgence of oxidative/nitrosative stress [46–49]. If for ROS overproduction mitochondrial malfunctioning is certainly imputed as the main cause [50], in the case of excessive RNS formation the main origin is linked to overexpression of inducible nitric oxide synthase (iNOS) with a consequent high rate of nitric oxide generation [51], often mediated by (neuro)inflammatory processes [52,53]. In preclinical and clinical studies of ALS, clear evidence of ROS and RNS-mediated damages have previously been shown [54–57] accompanied by a decrease in brain and muscle concentrations of reduced glutathione [58,59], i.e., one of the most important intracellular water-soluble antioxidant and scavenger of excessive formation of nitric oxide and RNS [60]. In the cohort of patients with ALS, we found that both MDA (quantified by direct HPLC method with no derivatization) and the sum of nitrite + nitrate were, before treatment, significantly higher than the values recorded in healthy controls. Although ILB® administration did not abolish evidence of circulating oxidative/nitrosative stress associated with ALS, a significant decrease in both parameters was evident one week after the 29 days period of drug treat-
ment. Additionally, patients with ALS post ILB® treatment had significantly higher serum levels of the main fat-soluble antioxidants (the \(\alpha\)- and \(\gamma\)-congeners of tocopherol) that may confer better protection to unsaturated fatty acids of biological membrane phospholipids towards ROS-mediated lipid peroxidation. It is worth underlining that ILB® displayed, under different experimental conditions, remarkable anti-inflammatory activity [5] and capacity to diminish oxidative/nitrosative stress [6].

The last beneficial effects of the ILB® administration to this cohort of patients with ALS were changes in serum levels of ALA, CITR and the ORN/CITR ratio when compared with the corresponding pre-treatment levels. In the pre-treatment samples, these parameters were significantly different from those of controls (higher ALA and CITR, and lower ORN/CITR ratio), suggesting higher degradation rate of muscular proteins (ALA) and confirming higher nitric oxide production through higher activity of the iNOS enzymes (CITR and ORN/CITR ratio). Previous data indicate various anomalies in the tissue and serum levels of free amino acids [61–64], supporting the notion of a profound metabolic derangement induced by ALS. The benefits of ILB® treatment on these parameters confirm the data obtained with sum of nitrite + nitrate and suggest that the drug may affect positively muscle metabolism perhaps either through its anti-inflammatory activities [5] or through its capacity to induce an amelioration of energy-related metabolism and of amino acid metabolism dysregulation under conditions of cell sufferance [6].

In conclusion, although obtained in a restricted number of patients (not allowing to evaluate potential age and/or sex differences of the serum biochemical analyses) this longitudinal study produced very encouraging results concerning the effects of ILB® administration to patients suffering from ALS. As there are no current effective drug treatments licensed for clinical use other than riluzole that has a very limited benefit, the present findings indicate the utility of pharmacological interventions positively acting on the ALS-induced metabolic changes, specifically on energy-related mitochondrial functions, oxidative/nitrosative stress and amino acid metabolism. Results from further studies with larger patient numbers are needed.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/jpm11080794/s1, Table S1: Clinical trial protocol, Table S2: Raw data reporting the circulating concentrations of hypoxanthine (HYP), xanthine (XAN), uric acid, malondialdehyde (MDA), nitrite (-NO\(_2\)), nitrate (-NO\(_3\)), N-acetylaspartate (NAA), nitrite + nitrate and sum of oxypurines (hypoxanthine + xanthine + uric acid), detected in serum of each ALS patient included in the study, before and after ILB® administration, Table S3: Raw data reporting the circulating concentrations of citrulline (CITR), alanine (ALA), ornithine/citrulline ratio (ORN/CITR) detected in serum of each ALS patient included in the study, before and after ILB® administration, Table S4: Raw data reporting the circulating concentrations of the two main congeners of vitamin E (\(\alpha\)-tocopherol and \(\gamma\)-tocopherol) detected in serum of each ALS patient included in the study, before and after ILB® administration, Table S5: Raw data reporting the circulating concentrations of the relevant metabolites detected in serum of healthy controls.

**Author Contributions:** Conceptualization, L.I.P., L.B., A.L., Z.N., N.M.B., G.L. (Giuseppe Lazzarino) and B.T.; methodology, G.L. (Giacomo Lazzarino), B.T., B.M.R., A.M.A., M.W.S. and L.I.P.; validation, A.L., Z.N., N.M.B., G.L. (Giuseppe Lazzarino) and B.T.; formal analysis, G.L. (Giacomo Lazzarino), R.M., B.M. and B.T.; investigation, B.M.R., G.L. (Giuseppe Lazzarino) and B.T.; resources, L.B.; data curation, G.L. (Giacomo Lazzarino), R.M., B.M., A.M.A., M.W.S., G.L. (Giuseppe Lazzarino) and B.T.; writing—original draft preparation, A.L. and G.L. (Giuseppe Lazzarino); writing—review and editing, A.L., G.L. (Giuseppe Lazzarino), B.T., G.L. (Giacomo Lazzarino), Z.N., N.M.B., L.B., A.B., V.D.P. and L.I.P.; supervision, B.T.; project administration, A.L.; funding acquisition, L.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Tikomed AB, who had no influence on the conduct of the trial and was not involved in data collection or analysis.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was overseen and approved by the Ethics Committee of the University of Gothenburg and by the Swedish Medical Products Agency (reference number 21788).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The underpinning data that support the findings in this study are available from the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005065-47/results, accessed on 5 September 2020).

Acknowledgments: This study was funded by Tikomed AB. The authors would like to thank the patients participating in the study as well as their clinical and nursing staff at the Sahlgrenska University Hospital. In addition, the authors acknowledge the contribution of Kaj Blennow, Ewa Johansson, Stefan Lange of the Sahlgrenska Academy, University of Gothenburg, for help with data collection.

Conflicts of Interest: Patents pertaining to this LMW-DS drug have been filed by Tikomed AB. L.B. is co-inventor of the LMW-DS used in the study and is a board member of Tikomed AB. A.L., Z.N., N.M.B. and A.B. declare consultancy payments from Tikomed AB and/or Neuregenix Ltd. for related services outside the submitted work. The authors declare that they have no competing interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Mitchell, J.D.; Borasio, G.D. Amyotrophic lateral sclerosis. Lancet 2007, 369, 2031–2041. [CrossRef]
2. Andrews, J.A.; Jackson, C.E.; Heiman-Patterson, T.D.; Bettica, P.; Brooks, B.R.; Pioro, E.P. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020, 21, 509–518. [CrossRef] [PubMed]
3. Le Gall, L.; Anakor, E.; Connolly, O.; Vijayakumar, U.G.; Duddy, W.J.; Duguez, S. Molecular and cellular mechanisms affected in ALS. J. Pers. Med. 2020, 10, 101. [CrossRef]
4. Aydemir, D.; Ulusu, N.N. Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS. Med. Hypotheses 2020, 141, 109736. [CrossRef]
5. von Zur-Mühlen, B.; Lundgren, T.; Bayman, L.; Berne, C.; Bridges, N.; Eggerman, T.; Foss, A.; Goldstein, J.; Jenssen, T.; Jorns, C.; et al. Open randomized multicenter study to evaluate safety and efficacy of low molecular weight sulphated dextran in islet transplantation. Transplantation 2019, 103, 630–637. [CrossRef] [PubMed]
6. Lazzarino, G.; Amorini, A.M.; Barnes, N.M.; Bruce, L.; Mordente, A.; Lazzarino, G.; Di Pietro, V.; Tavazzi, B.; Belli, A.; Logan, A. Low molecular weight dextran sulfate (ILB®) restores brain energy metabolism following severe traumatic brain injury in the rat. Antioxidants 2020, 9, 850. [CrossRef]
7. Logan, A.; Nagy, Z.; Barnes, N.M.; Belli, A.; Di Pietro, V.; Tavazzi, B.; Lazzarino, G.; Lazzarino, G.; Bruce, L.; Ropero, B.M.; et al. A phase II open label clinical study of the safety, tolerability and efficacy of a low molecular weight dextran sulphate for Amyotrophic Lateral Sclerosis. PLoS ONE 2021, submitted.
8. A Single-Centre, Open Single-Arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will Be Evaluated in Patients with Amyotrophic Lateral Sclerosis. Available online: URLhttps://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005065-47/results (accessed on 11 May 2021).
9. Cedarbaum, J.M.; Stambler, N.; Malta, E.; Fuller, C.; Hilt, D.; Thurmond, B.; Nakanishi, A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 1999, 169, 13–21. [CrossRef]
10. Lazzarino, G.; Amorini, A.M.; Fazzina, G.; Vagnozzi, R.; Signoretto, S.; Donzelli, S.; Di Stasio, E.; Giardina, B.; Tavazzi, B. Single-sample preparation for simultaneous cellular redox and energy state determination. Anal. Biochem. 2003, 322, 51–59. [CrossRef] [PubMed]
11. Tavazzi, B.; Lazzarino, G.; Leone, P.; Amorini, A.M.; Bellia, F.; Janson, C.G.; Di Pietro, V.; Ceccarelli, L.; Donzelli, S.; Francis, J.S.; et al. Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. Clin. Biochem. 2005, 38, 997–1008. [CrossRef] [PubMed]
12. Lazzarino, G.; Longo, S.; Amorini, A.M.; Di Pietro, V.; D’Urso, S.; Lazzarino, G.; Belli, A.; Tavazzi, B. Single-step preparation of selected biological fluids for the high performance liquid chromatographic analysis of fat-soluble vitamins and antioxidants. J. Chromatogr. A 2017, 1527, 43–52. [CrossRef]
13. Romitielli, F.; Santini, S.A.; Chierici, E.; Pitocco, D.; Tavazzi, B.; Amorini, A.M.; Lazzarino, G.; Di Stasio, E. Comparison of nitrite/nitrate concentration in human plasma and serum samples measured by the enzymatic batch Griess assay, ion-pairing HPLC and ion-trap GC-MS: The importance of a correct removal of proteins in the Griess assay. J. Chromatogr. B 2007, 851, 257–267. [CrossRef] [PubMed]
14. Amorini, A.M.; Giorlandino, C.; Longo, S.; D’Urso, S.; Mesoraca, A.; Santoro, M.L.; Picardi, M.; Gullotta, S.; Cignini, P.; Lazzarino, D.; et al. Metabolic profile of amniotic fluid as a biochemical tool to screen for inborn errors of metabolism and fetal anomalies. *Mol. Cell. Biochem.* 2012, 359, 205–216. [CrossRef]

15. Artiss, J.D.; Karcher, R.E.; Cavanagh, K.T.; Collins, S.L.; Peterson, V.J.; Varma, S.; Zak, B. A liquid-stable reagent for lactic acid levels. Application to the Hitachi 911 and Beckman CX7. *Am. J. Clin. Pathol.* 2000, 114, 139–143. [CrossRef] [PubMed]

16. Sharma, C.; Kim, S.; Nam, Y.; Jung, U.; Kim, S.R. Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease. *Int. J. Mol. Sci.* 2021, 22, 4850. [CrossRef] [PubMed]

17. Nunes, C.; Laranjinha, J. Nitric oxide and dopamine metabolism converge via mitochondrial dysfunction in the mechanisms of neurodegeneration in Parkinson’s disease. *Arch. Biochem. Biophys.* 2021, 704, 108877. [CrossRef] [PubMed]

18. Noori, A.; Mezlini, A.M.; Hyman, B.T.; Serrano-Pozo, A.; Das, S. Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. *Neurobiol. Dis.* 2021, 149, 105225. [CrossRef]

19. McDonald, T.S.; McCombe, P.A.; Woodruff, T.M.; Lee, J.D. The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. *FASEB J.* 2020, 34, 7225–7233. [CrossRef] [PubMed]

20. Straub, I.R.; Weraarpachai, W.; Shobruby, E.A. Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses. *Hum. Mol. Genet.* 2021, 30, 687–705. [CrossRef] [PubMed]

21. Gerou, M.; Hall, B.; Wof, R.; Asslop, J.; Kolb, S.J.; Meyer, K.; Shaw, P.J.; Allen, S.P. Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts. *Neurobiol. Aging* 2021, 105, 64–77. [CrossRef] [PubMed]

22. Allen, S.P.; Hall, B.; Castelli, L.M.; Francis, L.; Wof, R.; Siskos, A.P.; Kouloura, E.; Gray, E.; Thompson, A.G.; Talbot, K.; et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. *Brain* 2019, 142, 586–605. [CrossRef] [PubMed]

23. Tefera, T.W.; Steyn, F.J.; Ngo, S.T.; Borges, K. CNS glucose metabolism in Amyotrophic Lateral Sclerosis: A therapeutic target? *Cell Biosci.* 2021, 11, 14. [CrossRef] [PubMed]

24. Ohba, Y.; Yamashita, T.; Nomura, E.; Hishikawa, N.; Ikegami, K.; Osaka, Y.; Matsumoto, N.; Kawaihara, Y.; Yunoki, T.; Takahashi, Y.; et al. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. *J. Neurol. Sci.* 2020, 415, 116906. [CrossRef] [PubMed]

25. Simone, I.L.; Ruggieri, M.; Tortelli, R.; Ceci, E.; D’Errico, M.; Leo, A.; Zoccolella, S.; Masrapasqua, M.; Capozzo, R.; Livrea, P.; et al. Serum N-acetylglutaminpeptide level in patient derived fibroblasts. *Arch. Neurol.* 2011, 68, 1308–1312. [CrossRef] [PubMed]

26. Weerasekera, A.; Peeters, R.; Sima, D.M.; Dresselaers, T.; Sunaert, S.; De Vocht, J.; Claeys, K.; Van Huffel, S.; Van Damme, P.; Himmelreich, U. Motor cortex metabolite alterations in amyotrophic lateral sclerosis assessed in vivo using edited and non-edited magnetic resonance spectroscopy. *Brain Res.* 2019, 1718, 22–31. [CrossRef]

27. Reischauer, C.; Gutzeit, A.; Neuwirth, C.; Fuchs, A.; Sartoretti-Schefer, S.; Weber, M.; Czell, D. In-vivo evaluation of neuronal and glial changes in amyotrophic lateral sclerosis with diffusion tensor spectroscopy. *Neuroimage Clin.* 2018, 20, 999–1000. [CrossRef] [PubMed]

28. Ratai, E.M.; Alishko, M.J.; Zürcher, N.R.; Loggia, M.L.; Cebulla, C.L.; Cernasov, P.; Reynolds, B.; Fish, J.; Seth, R.; Babu, S.; et al. Integrated imaging of (11C)-PET/28 PET, MR diffusion and magnetic resonance spectroscopy (1)H-MRS in amyotrophic lateral sclerosis. *Neuroimage Clin.* 2018, 20, 357–364. [CrossRef] [PubMed]

29. Hanstock, C.; Sun, K.; Choi, C.; Eurich, D.; Camicioni, R.; Johnston, W.; Kalra, S. Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in amyotrophic lateral sclerosis. *Amyotroph. Lateral Scler. Front. Degener.* 2020, 21, 246–251. [CrossRef] [PubMed]

30. Vicario, N.; Spitale, F.M.; Tibullo, D.; Giallongo, C.; Amorini, A.M.; Scandura, G.; Spoto, G.; Saab, M.W.; D’Aprile, S.; Alberghina, C.; et al. Clopectalitrom promotes neumorphomcellular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing. *Cell Death Dis.* 2021, 12, 625. [CrossRef]

31. Vagnozzi, R.; Marmarou, A.; Tavazzi, B.; Signoretti, S.; Di Pierro, D.; del Bolgia, F.; Amorini, A.M.; Fazzina, G.; Sherkat, S.; Lazzarino, G. Changes of cerebral energy metabolism and lipid peroxidation in rats leading to mitochondrial dysfunction after diffuse brain injury. *J. Neurotrauma* 1999, 16, 903–913. [CrossRef]

32. Vagnozzi, R.; Signoretti, S.; Marmarou, A.; Ayyog, G.A.; Fatouros, P.P.; Portella, G.; Bullock, R.M. Assessment of mitochondrial impairment in traumatic brain injury in young mice. *J. Neurosurg.* 2008, 108, 42–52. [CrossRef] [PubMed]

33. Belli, A.; Sen, J.; Petzold, A.; Russo, S.; Kitchen, N.; Smith, M.; Tavazzi, B.; Vagnozzi, R.; Signoretti, S.; Amorini, A.M.; et al. Extracellular N-acetylaspartate depletion in traumatic brain injury. *J. Neurochem.* 2006, 96, 861–869. [CrossRef] [PubMed]

34. Vagnozzi, R.; Signoretti, S.; Tavazzi, B.; Floris, R.; Ludovici, A.; Marziali, S.; Tarasco, G.; Amorini, A.M.; Di Pietro, V.; Delfini, R.; et al. Temporal window of metabolic brain vulnerability to concussion: A pilot study. *J. Neurotrauma* 2008, 25, 1286–1295. [CrossRef] [PubMed]

35. Vagnozzi, R.; Signoretti, S.; Cristofori, L.; Alessandrin, F.; Floris, R.; Isgrò, E.; Ria, A.; Marzia, S.; Zoccatelli, G.; Tavazzi, B.; et al. Assessment of metabolic brain damage and recovery following mild traumatic brain injury: A multicentre, proton magnetic resonance spectroscopic study in concussed athletes—part III. *Neurosurgery* 2008, 62, 1286–1295. [CrossRef] [PubMed]

36. Toczek, M.; Zielonka, D.; Zukowska, P.; Marcinkowski, J.T.; Słominska, E.; Isalan, M.; Smolenski, R.T.; Mielcarek, M. An impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington’s disease related cardiomyopathy. *Biochim. Biophys. Acta* 2016, 1862, 2147–2157. [CrossRef] [PubMed]
37. Van Wylen, D.G. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. *Circulation* 1994, 89, 2283–2289. [CrossRef] [PubMed]

38. Lazzarino, G.; Raatikainen, P.; Nuutinen, M.; Nissinen, J.; Tavazzi, B.; Di Pietro, D.; Giardina, B.; Peuhkurinen, K. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. *Circulation* 1994, 90, 291–297. [CrossRef] [PubMed]

39. Cristofori, L.; Tavazzi, B.; Gambin, R.; Vagnozzi, R.; Vivenza, C.; Amorini, A.M.; Di Pietro, D.; Fazzina, G.; Lazzarino, G. Early onset of lipoperoxidation after human traumatic brain injury: A fatal limitation for the free radical scavenger pharmacological therapy? *J. Investig. Med.* 2001, 49, 450–458. [CrossRef] [PubMed]

40. Lazzarino, G.; Amorini, A.M.; Petzold, A.; Gasperini, C.; Ruggieri, S.; Quartuccio, M.E.; Lazzarino, G.; Di Stasio, E.; Tavazzi, B. Serum compounds of energy metabolism impairment are related to disability, disease course and neuroimaging in multiple sclerosis. *Mol. Neurobiol.* 2017, 54, 7520–7533. [CrossRef] [PubMed]

41. Lazzarino, G.; Amorini, A.M.; Eikelenboom, M.; Killestein, J.; Belli, A.; Di Pietro, V.; Tavazzi, B.; Barkhof, F.; Polman, C.; Uitdehaag, B.; et al. Cerebrospinal fluid ATP metabolites in multiple sclerosis. *Mult. Scler. J.* 2010, 16, 549–554. [CrossRef] [PubMed]

42. Tavazzi, B.; Amorini, A.M.; Fazzina, G.; Di Pietro, D.; Tuttobene, M.; Giardina, B.; Lazzarino, G. Oxidative stress induces impairment of human erythrocyte energy metabolism through the oxygen radical-mediated direct activation of AMP-deaminase. *J. Biol. Chem.* 2001, 276, 48083–48092. [CrossRef] [PubMed]

43. Bracko, O.; Di Pietro, V.; Lazzarino, G.; Amorini, A.M.; Tavazzi, B.; Artmann, J.; Wong, E.C.; Buxton, R.B.; Weller, M.; Luft, A.R.; et al. 3-Nitropropionic acid-induced acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. *J. Cereb. Blood Flow Metab.* 2014, 34, 1522–1530. [CrossRef] [PubMed]

44. Vagnozzi, R.; Tavazzi, B.; Signoretti, S.; Amorini, A.M.; Belli, A.; Cimatti, M.; Delfini, R.; Di Pietro, V.; Finocchiaro, A.; Lazzarino, G. Temporal window of metabolic brain vulnerability to concussions: Mitochondrial-related impairment—part I. *Neurosurgery* 2007, 61, 379–388. [CrossRef] [PubMed]

45. Sassani, M.; Alix, J.J.; McDermott, C.J.; Baster, K.; Hoggard, N.; Wild, J.M.; Mortiboy, H.J.; Shaw, P.J.; Wilkinson, I.D.; Jenkins, T.M. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. *Brain* 2020, 143, 3603–3618. [CrossRef] [PubMed]

46. Ramachandra, C.J.A.; Hernandez-Resendiz, S.; Crespo-Avila, G.E.; Lin, Y.-H.; Hausenloy, D.J. Mitochondria in acute myocardial infarction and cardioprotection. *EBioMedicine* 2020, 57, 102884. [CrossRef] [PubMed]

47. Kaur, I.; Behl, T.; Sehgal, A.; Singh, S.; Sharma, N.; Aleya, L.; Bungau, S. Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: Focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity. *Environ. Sci. Pollut. Res. Int.* 2021, 28, 37060–37081. [CrossRef] [PubMed]

48. Sahel, D.K.; Kaira, M.; Raj, K.; Sharma, S.; Singh, S. Mitochondrial dysfunction and neuroinflammation: Recent highlights on the possible mechanisms involved in Traumatic Brain Injury. *Neurosci. Lett.* 2019, 710, 134347. [CrossRef] [PubMed]

49. Moosavi, B.; Zhu, X.L.; Yang, W.C.; Yang, G.F. Molecular pathogenesis of tumorigenesis caused by succinate dehydrogenase complex subunit D (SDHD) mutations. *Int. J. Mol. Sci.* 2019, 20, 151057. [CrossRef] [PubMed]

50. Tavazzi, B.; Vagnozzi, R.; Signoretti, S.; Amorini, A.M.; Belli, A.; Cimatti, M.; Delfini, R.; Di Pietro, V.; Finocchiaro, A.; Lazzarino, G. Temporal window of metabolic brain vulnerability to concussions: Oxidative and nitrosative stresses—part II. *Neurosurgery* 2007, 61, 390–395. [CrossRef] [PubMed]

51. Pérez-Torres, I.; Manzano-Pech, L.; Rubio-Ruiz, M.E.; Soto, M.E.; Guarnier-Lans, V. Nitrosative Stress and Its Association with Cardiometabolic Disorders. *Molecules* 2020, 25, 2555. [CrossRef] [PubMed]

52. Król, M.; Kepinska, M. Human Nitric Oxide Synthase—Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases. *Int. J. Mol. Sci.* 2020, 22, 56. [CrossRef] [PubMed]

53. Illes, P.; Rubini, P.; Ulrich, H.; Zhao, Y.; Tang, Y. Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS. *Cells* 2020, 9, 1108. [CrossRef] [PubMed]

54. Debksa-Vielhaber, G.; Miller, I.; Pera, V.; Zuschschatte, W.; Walczak, J.; Schreiber, S.; Petri, S.; Machts, J.; Vogt, S.; Szczepanowska, J.; et al. Impairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers. *Exp. Neurol.* 2021, 339, 113620. [CrossRef] [PubMed]

55. Devos, D.; Moreau, C.; Kyheng, M.; Garçon, G.; Rolland, A.S.; Blasco, H.; Gelé, P.; Lenglet, T.T.; Veyrat-Durebex, C.; Corcia, P.; et al. A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. *Sci. Rep.* 2019, 9, 2918. [CrossRef] [PubMed]

56. Golenia, A.; Leśkiewicz, M.; Regulski, M.; Budziszewska, B.; Szczysny, E.; Jagiella, J.; Wnuk, M.; Ostrowskam, M.; Lasoń, W.; Basta-Kaim, A.; et al. Catalase activity in blood fractions of patients with sporadic ALS. *Pharmacol. Rep.* 2014, 66, 704–707. [CrossRef] [PubMed]

57. Schonhoff, C.M.; Matsuoka, M.; Tummala, H.; Johnson, M.A.; Estevéz, A.G.; Wu, R.; Kaimad, A.; Ricart, K.C.; Hashimoto, Y.; Gaston, B.; et al. S-nitrosothiol depletion in amyotrophic lateral sclerosis. *Proc. Natl. Acad. Sci. USA* 2006, 103, 2404–2409. [CrossRef] [PubMed]

58. Cheong, K.; Marjarska, M.; Deelchand, D.K.; Eberly, L.E.; Walk, D.; Öz, G. Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis. *Neuroimage. Res.* 2017, 42, 1833–1844. [CrossRef] [PubMed]

59. Weidutsch, N.; Mao, X.; Hupf, J.; Armstrong, N.; Kang, G.; Lange, D.J.; Mitsumoto, H.; Shungu, D.C. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. *Neurosci. Lett.* 2014, 570, 102–107. [CrossRef] [PubMed]
60. Kalinina, E.; Novichkova, M. Glutathione in Protein Redox Modulation through S-Glutathionylation and S-Nitrosylation. *Molecules* **2021**, *26*, 435. [CrossRef]

61. Blasco, H.; Garcon, G.; Patin, F.; Veyrat-Durebex, C.; Boyer, J.; Devos, D.; Vourc’h, P.; Andres, C.R.; Corcia, P. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. *Can. J. Neurol. Sci.* **2017**, *44*, 90–95. [CrossRef]

62. Valbuena, G.N.; Rizzardini, M.; Cimini, S.; Siskos, A.P.; Bendotti, C.; Cantoni, L.; Keun, H.C. Metabolomic Analysis Reveals Increased Aerobic Glycolysis and Amino Acid Deficit in a Cellular Model of Amyotrophic Lateral Sclerosis. *Mol. Neurobiol.* **2016**, *53*, 2222–2240. [CrossRef] [PubMed]

63. Palma, A.; de Carvalho, M.; Barata, N.; Evangelista, T.; Chicau, P.; Regalla, M.; Costa, J. Biochemical characterization of plasma in amyotrophic lateral sclerosis: Amino acid and protein composition. *Amyotroph. Lateral Scler.* **2005**, *6*, 104–110. [CrossRef]

64. Bereman, M.S.; Kirkwood, K.I.; Sabaretnam, T.; Furlong, S.; Rowe, D.B.; Guillemin, G.J.; Mellinger, A.L.; Muddiman, D.C. Metabolite Profiling Reveals Predictive Biomarkers and the Absence of beta-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis. *J. Proteome Res.* **2020**, *19*, 3276–3285. [CrossRef] [PubMed]